- Home
- VLCN vs BDRX Comparison
VLCN vs BDRX Comparison
Compare VLCN & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLCN
- BDRX
- Stock Information
- Founded
- VLCN 2020
- BDRX 2000
- Country
- VLCN United States
- BDRX United Kingdom
- Employees
- VLCN N/A
- BDRX N/A
- Industry
- VLCN Auto Manufacturing
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- VLCN Consumer Discretionary
- BDRX Health Care
- Exchange
- VLCN Nasdaq
- BDRX Nasdaq
- Market Cap
- VLCN 3.0M
- BDRX 3.6M
- IPO Year
- VLCN 2021
- BDRX N/A
- Fundamental
- Price
- VLCN $0.64
- BDRX $1.28
- Analyst Decision
- VLCN
- BDRX
- Analyst Count
- VLCN 0
- BDRX 0
- Target Price
- VLCN N/A
- BDRX N/A
- AVG Volume (30 Days)
- VLCN 95.5K
- BDRX 158.8K
- Earning Date
- VLCN 05-09-2025
- BDRX 05-23-2025
- Dividend Yield
- VLCN N/A
- BDRX N/A
- EPS Growth
- VLCN N/A
- BDRX N/A
- EPS
- VLCN N/A
- BDRX N/A
- Revenue
- VLCN $3,739,692.00
- BDRX N/A
- Revenue This Year
- VLCN N/A
- BDRX N/A
- Revenue Next Year
- VLCN N/A
- BDRX N/A
- P/E Ratio
- VLCN N/A
- BDRX N/A
- Revenue Growth
- VLCN 19.70
- BDRX N/A
- 52 Week Low
- VLCN $0.66
- BDRX $1.14
- 52 Week High
- VLCN $330.40
- BDRX $74.00
- Technical
- Relative Strength Index (RSI)
- VLCN 30.44
- BDRX 37.92
- Support Level
- VLCN $0.66
- BDRX $1.11
- Resistance Level
- VLCN $0.78
- BDRX $1.38
- Average True Range (ATR)
- VLCN 0.05
- BDRX 0.09
- MACD
- VLCN -0.00
- BDRX 0.01
- Stochastic Oscillator
- VLCN 0.05
- BDRX 40.00
About VLCN Volcon Inc. Common stock
Volcon Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.